Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00378209 · OUTCOME

Overall Survival

Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma · Source last updated 2016-11-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
month
Interval / dispersion
95% Confidence Interval
Time frame
assesed at a median follow-up of 44 months

What was measured

defined as time from treatment initiation to death, or last known to be alive for those who had not died

Groups in this outcome

Lenalidomide, Dexamethasone, Bortezomib Combination

Not reported

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Lenalidomide, Dexamethasone, Bortezomib Combination64

Reported measurements

Source class 1
Values in month · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Lenalidomide, Dexamethasone, Bortezomib Combination30Not reported2437Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        24
        upper Limit
        37
        value
        30
denoms
  1. counts
    1. group Id
      OG000
      value
      64
    units
    Participants
description
defined as time from treatment initiation to death, or last known to be alive for those who had not died
dispersion Type
95% Confidence Interval
groups
  1. id
    OG000
    title
    Lenalidomide, Dexamethasone, Bortezomib Combination
param Type
MEDIAN
reporting Status
POSTED
time Frame
assesed at a median follow-up of 44 months
title
Overall Survival
type
SECONDARY
unit Of Measure
month

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice